tchp Antibody

What is TCHP antibody and what protein does it target?

TCHP antibody is a research tool designed to detect and study the TCHP protein (Trichoplein), also known as MGC10854. According to product information, it is produced in rabbit as an affinity isolated antibody and supplied in a buffered aqueous glycerol solution . The antibody targets the unmodified form of human TCHP protein (gene ID 84260) . This antibody enables researchers to visualize and quantify this protein in biological samples.

What are the main applications of TCHP antibody in research?

TCHP antibody is primarily used in immunohistochemistry and Western blotting applications . It enables detection of TCHP protein distribution in tissue samples and cell lysates. The antibody is valuable for studying TCHP's biochemical functions, as this protein has been shown to prevent cell growth when expressed de novo, block colony formation, and decrease DNA synthesis rates in transformed cell lines . The antibody has been extensively tested in the Human Protein Atlas project against hundreds of normal and disease tissues .

How should researchers store and handle TCHP antibody for optimal stability?

TCHP antibody should be stored at −20°C according to manufacturer guidelines . For maximum stability, researchers should:

• Avoid repeated freeze-thaw cycles by creating working aliquots

• Maintain the antibody in its buffered aqueous glycerol solution

• Handle according to good laboratory practices

• Follow specific manufacturer recommendations for storage duration

• Consider the potential impact of preservatives like sodium azide when designing experiments

What protocols yield optimal results when using TCHP antibody in immunohistochemistry?

While specific protocol details for TCHP antibody aren't provided in the search results, researchers should follow standard immunohistochemistry procedures with attention to:

• Tissue preparation: Proper fixation is critical; formalin-fixed paraffin-embedded tissues are typically used in validation studies

• Antigen retrieval: Optimize based on manufacturer recommendations

• Blocking: Use appropriate blocking reagents to minimize non-specific binding

• Antibody dilution: Determine optimal concentration through titration experiments

• Detection system: Choose appropriate secondary antibodies and visualization methods

• Controls: Include positive and negative controls in each experiment

The antibody has been validated by the Human Protein Atlas project through testing on tissue arrays of 44 normal human tissues and 20 common cancer types , suggesting robust performance across diverse tissue types.

What are effective protocols for using TCHP antibody in Western blotting applications?

For Western blotting with TCHP antibody, researchers should:

• Sample preparation: Use appropriate lysis buffers with protease inhibitors

• Protein separation: Optimize polyacrylamide gel percentage based on TCHP's molecular weight

• Transfer conditions: Determine optimal transfer time and voltage for TCHP

• Blocking: Test different blocking agents (BSA vs. non-fat milk) to minimize background

• Antibody incubation: Optimize primary antibody dilution, incubation time, and temperature

• Washing: Use stringent washing to reduce non-specific binding

• Detection: Select appropriate secondary antibody and detection method based on sensitivity requirements

The antibody has been verified for Western blotting applications according to product information , though specific optimization parameters should be determined empirically for each experimental system.

How can researchers validate the specificity of TCHP antibody in their experimental systems?

Researchers should implement multiple validation strategies:

• Antigen controls: Prestige antigen controls are available for corresponding Prestige Antibodies and can be found in the linkage section of product information

• Protein array testing: The antibody has been tested on arrays of 364 human recombinant protein fragments

• Orthogonal validation: Compare results across multiple detection techniques

• RNA correlation: Compare protein detection with RNA expression data

• Genetic models: Test in TCHP knockout/knockdown systems

• Cross-tissue comparison: Evaluate performance in tissues with varying TCHP expression levels

These approaches ensure that experimental findings truly reflect TCHP biology rather than non-specific interactions.

How does TCHP protein expression correlate with cancer progression and treatment response?

While direct data on TCHP protein expression in cancer is limited in the search results, researchers investigating this question should consider:

• Using TCHP antibody for immunohistochemical analysis of tissue microarrays representing cancer progression stages

• Correlating TCHP expression with clinical outcomes and treatment responses

• Investigating TCHP expression in the context of other biomarkers

• Examining subcellular localization changes during disease progression

The biochemical properties of TCHP suggest potential tumor suppressor functions, as "de novo expression of mitostatin prevents cell growth, mitostatin blocks the colony formation and decreases the rate of DNA synthesis in several transformed cell lines" . This makes TCHP a potentially interesting target for cancer research.

What methodological approaches can resolve contradictory findings when using TCHP antibody across different experimental systems?

When faced with contradictory results, researchers should:

• Antibody validation: Re-validate antibody specificity using multiple approaches

• Protocol standardization: Ensure consistent experimental conditions

• Sample preparation comparison: Evaluate the impact of different fixation/extraction methods

• Epitope accessibility assessment: Consider whether post-translational modifications or protein interactions might mask the epitope

• Quantification method analysis: Compare different approaches to quantifying TCHP levels

• Biological variability assessment: Determine whether differences reflect true biological variation

• Orthogonal measurements: Use alternative methods to confirm TCHP detection

This systematic approach can help resolve apparent contradictions and advance understanding of TCHP biology.

How can researchers integrate TCHP antibody-based detection with high-throughput sequencing approaches?

Integration of antibody-based detection with sequencing can provide powerful insights. Based on approaches used in similar research contexts:

• Chromatin immunoprecipitation sequencing (ChIP-seq): If TCHP has DNA-binding properties

• RNA immunoprecipitation sequencing (RIP-seq): To identify RNA molecules interacting with TCHP

• Proximity ligation assays combined with sequencing: To identify protein interaction partners

• Spatial transcriptomics with immunohistochemistry: To correlate TCHP protein localization with local gene expression

Study demonstrates how antibody-based techniques can be integrated with high-throughput sequencing in cancer research, offering a methodological framework that could be adapted for TCHP studies.

What strategies can address weak or inconsistent TCHP antibody staining in immunohistochemistry?

When encountering weak or inconsistent staining:

• Optimize antigen retrieval: Test multiple methods (heat-induced vs. enzymatic) and conditions

• Adjust antibody concentration: Perform titration experiments to identify optimal dilution

• Modify incubation conditions: Test different incubation times and temperatures

• Use signal amplification: Employ polymer-based detection systems or tyramide signal amplification

• Evaluate sample quality: Assess fixation adequacy and tissue processing quality

• Consider epitope accessibility: Determine if sample preparation affects the target epitope

• Compare detection systems: Test different visualization methods for sensitivity

Each parameter should be systematically optimized while maintaining appropriate controls.

How can researchers distinguish between specific and non-specific bands when using TCHP antibody in Western blotting?

To distinguish specific from non-specific bands:

• Positive control: Include samples with known TCHP expression

• Blocking peptide competition: Pre-incubate antibody with immunizing peptide

• Molecular weight verification: Confirm band appears at expected molecular weight

• Knockout/knockdown validation: Compare with samples lacking TCHP expression

• Alternative antibodies: Test antibodies recognizing different TCHP epitopes

• Loading controls: Ensure equal protein loading across samples

• Optimize blocking and washing: Reduce non-specific binding through protocol optimization

These approaches help ensure that observed bands truly represent TCHP rather than cross-reactive proteins.

What technical considerations are critical when designing multiplex experiments involving TCHP antibody?

For successful multiplex experiments:

• Antibody compatibility: Ensure primary antibodies are from different host species

• Fluorophore selection: Choose fluorophores with minimal spectral overlap

• Sequential staining: Consider sequential rather than simultaneous staining when necessary

• Cross-reactivity testing: Validate that secondary antibodies don't cross-react

• Signal strength normalization: Balance signal intensities across channels

• Controls: Include single-stain controls for accurate compensation

• Image acquisition settings: Optimize acquisition parameters for each channel

• Analysis approach: Develop quantification methods that account for potential bleed-through

Careful attention to these factors enables reliable co-localization studies involving TCHP and other proteins of interest.

How might TCHP antibody contribute to understanding immune responses in cancer treatment?

Research examining immune responses to cancer treatments could benefit from TCHP antibody applications:

Investigation of TCHP expression patterns could be integrated with immune repertoire analysis, similar to approaches used in study , which examined "the relationship between trastuzumab, docetaxel, carboplatin, and pertuzumab (TCHP) treatment and immune repertoire as a treatment response" in breast cancer . This study analyzed T-cell receptor (TCR) and B-cell receptor (BCR) repertoires before and after TCHP treatment, finding significant changes in diversity, density, and clonal composition .

Researchers could:

• Examine TCHP expression in relation to tumor-infiltrating lymphocytes

• Correlate TCHP levels with changes in immune cell populations following treatment

• Investigate potential associations between TCHP expression and immunotherapy response

What methodological approaches would best investigate TCHP's role in cell cycle regulation and mitochondrial function?

Based on TCHP's reported biochemical activities , researchers should consider:

• Cell cycle analysis: Combine TCHP immunofluorescence with cell cycle markers and flow cytometry

• Live-cell imaging: Use fluorescently-tagged TCHP to monitor dynamics during cell division

• Mitochondrial co-localization: Employ dual staining with mitochondrial markers

• Functional assays: Measure metabolic parameters in cells with modified TCHP expression

• Interaction proteomics: Identify TCHP binding partners using immunoprecipitation and mass spectrometry

• Structure-function analysis: Create domain mutants to map regions responsible for different activities

These approaches would help elucidate the molecular mechanisms underlying TCHP's reported ability to inhibit cell growth and DNA synthesis in transformed cell lines .

How can quantitative image analysis enhance the research value of TCHP antibody staining in tissue samples?

Researchers should:

• Establish reproducible image acquisition protocols

• Implement rigorous normalization procedures

• Develop automated analysis pipelines

• Validate quantitative findings with orthogonal approaches

• Correlate image-based measurements with functional outcomes

Such approaches would transform descriptive TCHP staining into quantitative data suitable for statistical analysis and correlation with clinical variables.